NCT01406587已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection
Pinnacle Pharmaceuticals, Inc.24 个研究点 分布在 1 个国家目标入组 261 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 261
- 试验地点
- 24
- 主要终点
- To assess the efficacy of PP4001 for the relief of burning during urination as measured by the subject's self-reported score at the time of urination in women with uUTI in comparison to placebo.
研究概览
简要总结
PP4001 is a medication not yet approved by the US FDA. This is a phase 2, multi-center, randomized, double-blind study of 3 doses of PP4001 versus placebo in the treatment of symptoms associated with uncomplicated urinary tract infection. After the screening, patients are randomized to receive one of three doses of PP4001 or placebo. Patients are screened and randomized on the same day, and take 4 doses of study drug, one dose every 12 hours. Data about uncomplicated urinary tract infection symptoms are collected from the subjects on electronic handheld devices throughout the 48-hour study period. The primary endpoint is burning during urination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects must be ≥ 18 and ≤ 75 years of age at the time of consent.
- •Females not of childbearing potential (FNCBP) are eligible for randomization. FNCBP are defined as postmenopausal women with their last menstrual cycle (without exogenous hormone therapy) completed more than 12 consecutive months before screening or women who are surgically sterilized (hysterectomy, oophorectomy, or tubal ligation). Females of childbearing potential also are eligible for randomization provided they are not pregnant or nursing and employ appropriate methods of contraceptives for the duration of the trial. Medically acceptable forms of contraception include abstinence, oral contraceptives, intra-uterine devices, injectable hormonals, intra-vaginal rings, or double-barrier methods (condom plus spermicide), for at least 1 month prior to treatment. Subjects in a monogamous, long term relationship with a partner who has had a vasectomy at least 3 months prior to screening are also study eligible.
- •Diagnosis of uncomplicated UTI as defined by having both of the following:
- •Presence of supporting symptoms including new onset (within 1 week) of urination frequency, painful urination, and/or urgency.
- •Positive dipstick test for leukocyte esterase.
- •Demonstration of moderate to severe burning during urination as measured by a score of at least six (6) on the 11-point rating scale for Burning During Urination during screening.
- •A negative urine pregnancy test for women of childbearing potential.
- •If subject has a chronic, clinically stable disease that requires medication, medication to treat that disease must be stable for at least 30 days prior to screening.
- •Ability to perform study procedures, including the completion of electronic diary assessments, and supply the necessary information to the study personnel as required by the protocol.
- •A signed informed consent form in which the subject agrees to participate after the study has been fully explained.
排除标准
- •Clinically significant medical history or a clinically significant abnormal finding on the physical exam, vital signs or ECG at screening, including serious acute illness (e.g. pneumonia), gastrointestinal illness that would interfere with study drug absorption, or an untreated or unstable medical illness that would likely interfere with the study assessments.
- •At risk in terms of the precautions, warnings, and contraindications in the package insert for phenazopyridine hydrochloride including:
- •Known hypersensitivity to phenazopyridine hydrochloride (Defined by a history of allergic or adverse response to the drug).
- •Renal failure or insufficiency (Defined as having a history of abnormal renal function or as having a known renal disease).
- •History of hepatic disease or failure (Defined as having known liver disease or having elevated LFTs (> 2 times the ULN) on previous laboratory testing. Patients who would not otherwise have such testing are not required to undergo special study labs).
- •Known G-6-PD (glucose-6-phosphate dehydrogenase) deficiency.
- •Prior use of a phenazopyridine product within 6 months of the first dose of study drug and throughout the study.
- •Use of any prescription analgesic medication (e.g. opioids, prescription nonsteroidal anti-inflammatory drugs (NSAID), etc.) for urinary tract pain or other pain (headache, back pain, joint pain, dental pain, sore muscles, etc) within one and a half (1.5) dosing intervals for that medication before the firs dose of study drug, and throughout the study.
- •Use of any systemic antibiotic within seven (7) days of study participation.
- •Subjects with complaint of abnormal vaginal discharge.
- •Current diagnosis or suspicion of complicated UTI or systemic infection based on one or more of the following:
- •Known presence of an anatomic or functional abnormality.
- •Presence of a urinary catheter.
- •Infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy.
- •Clinical signs of systemic infection such as fever (oral or tympanic temperature >38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting.
- •Subjects unable to comprehend the language of the informed consent and the self evaluation scales.
- •Subjects who, in the opinion of the investigator, are not appropriate for, or are unable, or unwilling to undergo antibiotic treatment for uncomplicated urinary tract infection.
- •Subjects with complaint of abnormal vaginal bleeding defined as different from the patient's usual menstrual period flow and timing.
- •Subjects with known allergy to multivitamin or any component of the multivitamin.
- •Currently participating in a clinical trial or has received an experimental drug or used an experimental device in the last 30 days prior to admission into this study.
- •Subjects who, in the opinion of the investigator, are unsuitable for enrollment, unlikely to complete the course of study medication treatment, or unlikely to attend the End of Study visit.
- •Subjects who are unable or unwilling to comply with the use of an electronic subject diary.
- •Employees of the investigator or the institution who have direct involvement in the trial or other trials under the direction of the investigator or their associates.
研究组 & 干预措施
PP4001 50 mg
Experimental
干预措施: PP4001 (Drug)
PP4001 100 mg
Experimental
干预措施: PP4001 (Drug)
PP4001 200 mg
Experimental
干预措施: PP4001 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
To assess the efficacy of PP4001 for the relief of burning during urination as measured by the subject's self-reported score at the time of urination in women with uUTI in comparison to placebo.
时间窗: Assessed at each urination from the time of randomization to 48 hours post first dose.
次要结局
- Change from baseline in the physical exam evaluation at the End of Study visit(The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.)
- To assess the efficacy of PP4001 for the relief of pain as measured by the subject's self-reported score at the time of urination.(Assessed at each urination from the time of randomization through 48 hours post first dose.)
- To assess the efficacy of PP4001 for reduction in urination frequency as measured by the subject's self-reported void diary.(Assessed at each urination from the time of randomization through 48 hours post first dose.)
- To evaluate the duration of therapeutic response to PP4001 50 mg, 100 mg and 200 mg.(Efficacy measures assessed in 2-hour windows after each dose.)
- To assess global assessment of uUTI symptom severity and change over time as measured by the subject-reported global assessment diaries.(Assessed at each urination from the time of randomization through 48 hours post first dose.)
- Change from baseline in vital signs at the End of Study visit(The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days after the End of Study Visit.)
- Change from baseline in ECG at the End of Study visit(The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.)
- Change from baseline in laboratory evaluations at the End of Study visit(The End of Study Visit is 48 - 100 hours post first dose. SAEs will be followed up to 30 days beyond the End of Study Visit.)
- Frequency, severity and relationship to study medication of treatment emergent adverse events(From first dose through the End of Study Visit (48 - 100 hours post first dose))
研究者
研究点 (24)
Loading locations...
相似试验
已完成
2 期
Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing ProstatectomyImpotenceProstate CancerNCT00090376Eisai Inc.240
Unknown
1 期
A Study of SYHA1805 in Healthy SubjectsHealthy SubjectsNCT04977570CSPC ZhongQi Pharmaceutical Technology Co., Ltd.36
已完成
2 期
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)MASHMetabolic Dysfunction-Associated SteatohepatitisNonalcoholic SteatohepatitisNASHNCT06342947Aligos Therapeutics102
已完成
2 期
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia TotalisAlopeciaNCT03594227Aclaris Therapeutics, Inc.87
终止
2 期
Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisPlaque PsoriasisNCT02201524Pfizer59